18:48 , Mar 20, 2019 |  BC Extra  |  Preclinical News

Peptomyc study details MYC-targeted cell-penetrating biologic

A new study from Peptomyc provides the latest evidence that cell-penetrating biologics can hit the previously intractable cancer target MYC. In a Science Translational Medicine paper, the company showed its mini-protein targeting MYC can reach...
12:55 , Sep 21, 2017 |  BC Innovations  |  Emerging Company Profile

Two leases on LIF

While most immuno-oncology products in the clinic target the immunosuppressive factors that help tumors evade an attack, Northern Biologics Inc. 's anti- LIF antibody takes a step further. By simultaneously blocking both immunosuppression and self-renewal...
00:28 , Jul 6, 2012 |  BC Extra  |  Financial News

Inbiomotion raises EUR 2 million in series A

Molecular diagnostics company Inbiomotion S.L. (Barcelona, Spain) raised EUR 2 million ($2.5 million) in a series A round led by new investor Ysios Capital. Fundacio Vila Casas and JVRisk Technologies also participated. Inbiomotion was spun...